Japanese vs. European View on Targeted Radionuclide Therapy
2025-12-01 10:00 - 11:00 (Europe/Vienna)
This event is a collaboration between ESMIT and JSNM. The aim of the webinar is to compare the approach to targeted radionuclide therapy (TRT) in Japan and in Europe. The webinar will focus on the differences in the TRT environment in Japan vs. Europe, including regulatory science and radiation protection regulation, and more.

Register nowEnrol in the live webinar now for free! Register now

Target Audience

Nuclear Medicine Physicians

Faculty

Tatsuya HigashiSpeaker

Wolfgang FendlerSpeaker

Conrad-Amadeus VoltinModerator

Event Overview

Nuclear Medicine in Breast Cancer Based on FOCUS Meeting 6
2025-12-04 08:00 - 2025-12-05 17:00 | Future Health Lab, Alfred-Adler-Straße 1, Vienna, 1100, Austria
Breast cancer is the most relevant cancer in women worldwide. It is the second most frequently diagnosed cancer (after lung cancer) and the first leading cause of cancer-related death in women, being the fourth globally regardless of gender. By 2040, breast cancer is predicted to increase to over 3 million new cases and 1 million deaths per year.

Staging patients with breast cancer is challenging due to its heterogeneous nature and presentation. Imaging is of utmost importance in all clinical settings, particularly, in staging, assessing therapy response, and detecting recurrence. Despite the well-stablished usefulness of radiologic modalities, Nuclear Medicine has demonstrated an important role to play in breast cancer, which has been increasingly supported by strong scientific evidence. Considering the patient’s long survival, the benefits of assessing active tumour in an accurate way, gain major importance in these patient’s care.

The recent equipment and radiopharmaceutical developments have opened the path to improve tumour characterization through several imaging possibilities. Currently, the challenge is to use the correct combination of equipment and tracer at the right time. Furthermore, homogenize imaging and clinical procedures is becoming even more important.

During this course, the highlights from the consensus reached during the multidisciplinary EANM Focus Meeting 6 about Nuclear Medicine diagnostics and therapeutics possibilities will be comprehensively presented and discussed in a close way between the faculty and attendees.

Register nowRegistration is now open, save yourself a seat! Register now

Learning Objectives

To understand breast cancer as a heterogeneous disease, its characteristics and evolution;

To define the role of nuclear medicine techniques in different clinical settings (initial staging, assessing therapy response, and detecting recurrence);

To know the potential usefulness of PET tracers beyond FDG in each breast cancer subtype and use of the evolving PET technology & equipment;

To discuss future diagnostic and treatment approaches with radiopharmaceuticals.

Target Audience

Nuclear Medicine physicians, Radiologists, Medical Oncologists, Radiation Oncologists, Medical students, Residents, Nurses, Nuclear Medicine technologists and Radiographers.

ProgrammeView the Programme

Faculty

Sofia VazSpeakerLisbon, Portugal

Thiemo van NijnattenSpeakerMaastricht, Netherlands

Philipp BackhausSpeakerMünster, Germany

Registration Details

Registration FeeMode of PaymentCancellation Policy

Course Fee € 950.-

Registration Fee includes:

Electronic Course Book, including all Slides

Coffee & Lunch Breaks

Registration Fee does NOT include:

Travel to the Venue

Accommodation

Registration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted

Cancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge. After this date, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.

To AI or not to AI in Neurology: That is the Question
2025-12-12 13:30 - 14:30
This webinar will explore state-of-the-art AI approaches for advancing neuroimaging, with a particular focus on quantitative PET. It will cover the entire imaging pipeline, from preprocessing, acquisition, and tomographic reconstruction to quantification, segmentation, denoising, and resolution enhancement, demonstrating how modern AI can enable more reproducible and robust brain PET biomarkers. Through two expert presentations and practical case examples, the webinar will showcase how AI-driven methodologies are reshaping neuroimaging research and supporting more accurate diagnosis and disease monitoring.

Register nowEnrol in the live webinar now for free! Register now

Learning Objectives

Learn the principles behind AI-based quantitative PET methods

Understand how AI can enhance each stage of the neuroimaging pipeline, from preprocessing and reconstruction to segmentation, denoising, and resolution recovery.

Critically assess when AI meaningfully improves neuroimaging workflows

Recognize emerging opportunities and challenges in integrating AI tools into brain PET

Target Audience

Nuclear physicians, medical physicists, imaging scientists and radiologists working in PET neuroimaging

Faculty

Pablo Aguilar FernándezModerator

Dimitris VisvikisSpeaker

Charalampos TsoumpasSpeaker

Event Overview

Fundamentals of Research in Imaging and Theranostics – Part 1: Research Design
2026-12-31 00:00 - 23:59 | Online
UEMS EACCME has granted the accreditation of 4 CME credits for this event.

This online course is part of a long line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation, as well as the design, conductance and reporting of clinical research trials, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications.

These first two modules will represent part one of the course.

Module 1 will focus on the entire path from preclinical development to clinical translation of an imaging compound, including the preclinical studies needed for the selection of a new candidate for clinical translation, an overview of EU legislation on radiopharmaceuticals for diagnosis and therapy, and the assessment of quality data and non-clinical data (pharmacology, dosimetry and toxicology) for the IMP dossier.

Module 2 will be focused on the design of a proper trial. It will cover: the definition of objectives, aims, endpoints, population, statistical methods and examples of trial design schemes, as well as dosimetry as far as healthy organs and in case of therapy tumour-absorbed dose. It will have a special focus on phase 0, phase 1-2 trial, early clinical phase 0-1-2 and investigator-driven clinical trial.

Save yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!

Learning Objectives:

Learn about:

Preclinical development and clinical translation of radiopharmaceuticals

The legislation on radiopharmaceuticals with a specific focus on the European scenario

Requirements of IMPD for radiopharmaceuticals for imaging agents and theranostic/therapeutic molecules Interpretation of preclinical data to properly design and plan the clinical trial

Phase 0, phase 1 and phase 2 clinical trials with radiopharmaceuticals design

Phase 0, phase 1 and phase 2 clinical trials with radiopharmaceuticals conductance

GMP, GLP and GCP principles

Importance of radioprotection and dosimetric estimates in early phase clinical trials

Target Audience:

Researchers, scientists, nurses, pharmacologists, radiopharmacists, residents and specialists in Nuclear Medicine/Oncology/Radiology who want to understand how clinical trials with radiopharmaceuticals in the early phase are unique and how the corresponding documents and trial design should be appropriately planned.

ProgrammeClick to see the full event programme. View the Programme

Faculty

Paola Anna ErbaUniversità degli Studi di Milano-Bicocca, Italy

Sona BalogovaComenius University, Bratislava, Slovakia

Elisabeth von GuggenbergMedical University Innsbruck, Austria

Martina SolliniVita-Salute San Raffaele University, Milan, Italy

Luigi AlojUniversity of Cambridge, United Kingdom

Meltem OcakIstanbul University, Turkey

Peter LavermanRadboud Universiteit Nijmegen, The Netherlands

Jane SosabowskiQueen Mary, University of London, United Kingdom

Petra KolencUniversity Medical Centre Ljubljana, Slovenia

Clemens DecristoforoMedical University Innsbruck, Austria

Piotr GarnuszekPOLATOM, Warsaw, Poland

Renata MikolajczakPOLATOM, Warsaw, Poland

Theodosia MainaNCSR Demokritos, Athens, Greece

Mark KonijnenbergErasmus MC, Rotterdam, The Netherlands

Registration Details

Registration Fee

Course Fee Free

Event Overview
